$VERUJul 27, 2026, 12:10 PMAI processed
Veru completes enrollment in Phase 2b PLATEAU trial of enobosarm + semaglutide; interim Q1'27
AI Summary
Veru (VERU) said it has fully enrolled ~200 older patients (≥65, BMI≥35) in the randomized Phase 2b PLATEAU study testing oral enobosarm 3 mg vs placebo added to semaglutide, with an interim analysis expected in Q1 2027 and topline data in Q4 2027. The trial’s primary endpoint is percent change in total body weight at 68 weeks and key secondaries (DXA-measured fat/lean mass, stair-climb physical function, bone mineral density) are intended to show whether enobosarm preserves lean mass and drives additional, higher-quality weight loss on top of GLP-1 therapy.
Positives
- Achieved full enrollment (~200 patients) in the randomized double-blind Phase 2b PLATEAU study
- Interim analysis planned for Q1 2027 and final topline data expected Q4 2027
- Builds on a prior positive Phase 2b QUALITY study that showed enobosarm preserved lean mass and increased fat loss when combined with semaglutide
Negatives
- No efficacy or safety data yet; meaningful readouts are months away (interim Q1'27, topline Q4'27)
- Novo Nordisk supplies semaglutide for the study but explicitly does not endorse enobosarm and the supply agreement can be terminated
- Study population is limited to older patients (≥65, BMI≥35), which may limit generalizability